Loading...
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino, M C Torri, V Michetti, G Lo Dico, M La Verde, N Aglione, S Mancuso, A Gallerani, E Galetta, D Martelli, O
Garassino, M C
Torri, V
Michetti, G
Lo Dico, M
La Verde, N
Aglione, S
Mancuso, A
Gallerani, E
Galetta, D
Martelli, O
Citations
Altmetric:
Abstract
Patients with small-cell lung cancer (SCLC) that progress after first-line chemotherapy have a poor prognosis and the evidence of a benefit from second-line (SL) chemotherapy is limited. Patients relapsing or progressing more than 90 days after completion of first-line treatment are considered platinum sensitive and may be rechallenged with platinum-based chemotherapy. Topotecan is approved as SL treatment independent of time to progression. This retrospective analysis evaluates the clinical outcomes of SCLC patients who received SL chemotherapy after platinum-etoposide chemotherapy.
Description
Date
2011-06
Publisher
Collections
Keywords
Type
Article
Citation
Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. 2011, 72 (3):378-83 Lung Cancer